MedTrace Logo

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

NCT00850161 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-02-15

No results posted yet for this study

Summary

The purpose of this study is to determine if glucose peaks higher and earlier after a meal when a patient is given intranasal insulin instead of conventional insulin treatment.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

aspart

Meal-time insulin. Administered subcutaneously based on routine clinical therapy.

DRUG

Nasulin™

100 IU(2 puffs in each nostril)

Sponsors & Collaborators

  • CPEX Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Adrian Vella, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-08-31
Completion
2010-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850161 on ClinicalTrials.gov